At Puma Biotechnology, our focus is on bringing innovative therapies to patients to enhance cancer care.
We are thankful to be part of the HER2+ breast cancer community and are passionate about evaluating options that may benefit patients across the breast cancer therapy spectrum.
We are thankful to be part of the HER2+ breast cancer community and are passionate about evaluating options that may benefit patients across the breast cancer therapy spectrum.
Location: United States, California, Los Angeles
Employees: 201-500
Total raised: $60M
Founded date: 2010
Investors 2
| Date | Name | Website |
| 13.07.2025 | Foresite C... | foresiteca... |
| - | Sahsen Ven... | sahsen.com |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 23.11.2011 | - | $60M | - |
Mentions in press and media 16
| Date | Title | Description |
| 26.07.2021 | Puma Biotechnology : Secures $125 Million Note Purchase by Athyrium Capital | Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that it has entered into a note purchase agreement with a fund of Athyrium Capital Management, LP, a specialized asset management company focused on opportuniti... |
| 27.02.2021 | Puma Biotechnology und Pierre Fabre ändern die NERLYNX®-Lizenzvereinbarung, die neu auch Großchina einbezieht | LOS ANGELES und CASTRES (Frankreich)--(BUSINESS WIRE)--Feb 27, 2021-- Das Biopharmaunternehmen Puma Biotechnology, Inc. (Nasdaq: PBYI), und das namhafte französische Pharmaunternehmen Pierre Fabre haben eine Verlängerung der Lizenzvereinbar... |
| 10.05.2019 | Puma investors fret, as Nerlynx Q1 sales fall uncomfortably short of Wall Street estimates | “We are not pleased with our first-quarter Nerlynx revenues,” Puma Biotechnology chief Alan Auerbach said in a post-earnings conference call on Thursday, citing a spate of disconcerting factors, including patient discon... |
| 19.03.2019 | Affimed lands milestone from Roche; Puma touts new PHII data on cervical cancer | → While Affimed $AFMD works to shake off the FDA hold on its Phase I program, the team is still making preclinical progress with its innate cell engager-based cancer therapies. The German biotech said its big partner at Genent... |
| 17.07.2017 | Puma’s controversial cancer drug secures FDA approval | On Monday, FDA (somewhat) settled that debate by granting it marketing approval. A tyrosine kinase inhibitor, neratinib works by blocking multiple enzymes that would otherwise promote cell growth. It’s indicated for HER2-positive tumors, a ... |
| 24.05.2017 | There’s a therapeutic curveball heading for the FDA | On Wednesday, FDA’s Oncologic Drugs Advisory Committee voted 12-4 in favor of recommending the tyrosine kinase inhibitor be approved. But the endorsements were far from emphatic and many doubts still swirl. FDA typically – but not always – ... |
| 17.04.2017 | CRISPR Therapeutics, Casebia ink AAV deal with StrideBio; Puma gets an AdComm date; Merrimack names new R&D chief | → CRISPR Therapeutics $CRSP and Casebia Therapeutics, a joint-venture established by CRISPR Therapeutics and Bayer AG, have inked a collaboration agreement with StrideBio to develop AAV vectors for in vivo gene del... |
| 23.11.2011 | Puma Biotechnology Raises $60M | Los Angeles-based Puma Biotechnology, a developer of biopharmaceuticals aimed at treating cancer, said this morning that it has completed a second tranche of a $60M private financing. The company said that Leerink Swann LLC was the lead pla... |
| - | There’s a therapeutic curveball heading for the FDA | Los Angeles, California-based Puma Biotechnology has shuffled a challenging new drug application (NDA) onto FDA’s desk. Neratinib has polarized experts and investors over the last few weeks, with its data flaws and dubious benefit-to-risk r... |
| - | Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) | LOS ANGELES--(BUSINESS WIRE)--Mar 8, 2021-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on March 4, 2021 the Compensation Committee of Puma’s Board of Directors approved the grant of an inducement re... |
Show more